Related Experiment Video

Updated: Jun 30, 2025

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.5K

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment

Caroline K Kramer1,2,3, Matthew Retnakaran1, Luciana V Viana4,5,6

  • 1Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, ON M5T 3L9, Canada.

The Journal of Clinical Endocrinology and Metabolism
|March 15, 2024
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote significant weight loss in patients post metabolic bariatric surgery (MBS). These medications, including liraglutide and semaglutide, offer an acceptable safety profile for managing weight regain after MBS.

Area of Science:

  • Endocrinology
  • Metabolic Surgery
  • Pharmacology

Background:

  • Weight regain is a concern after metabolic bariatric surgery (MBS).
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being explored for post-MBS weight management.
  • The efficacy and safety of GLP-1RAs in this patient population require systematic evaluation.

Purpose of the Study:

  • To systematically review and meta-analyze the impact of GLP-1RAs on weight changes in patients who have undergone MBS.
  • To assess the effectiveness of GLP-1RAs in promoting weight loss following bariatric procedures.

Main Methods:

  • Systematic review and meta-analysis of 17 studies involving 1164 participants.
  • Pooled analysis of observational studies and randomized controlled trials (RCTs).
  • Evaluation of weight changes from baseline and compared to placebo groups.

Main Results:

  • Observational studies showed a mean weight reduction of 7.83 kg post-MBS with GLP-1RA use.
  • RCTs indicated a weight reduction of 4.36 kg compared to placebo.
  • Adverse events were reported by 23% of participants, with 7% discontinuing treatment.

Conclusions:

  • Liraglutide and semaglutide effectively promote significant weight reduction in patients post-MBS.
  • GLP-1RA use in this context demonstrates an acceptable safety profile.
  • GLP-1RAs represent a viable strategy for managing weight regain after metabolic bariatric surgery.
Keywords:
GLP-1 RAbariatric treatmentliraglutidesemaglutideweight loss

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.6K
A Murine Model of Vertical Sleeve Gastrectomy06:47

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

11.1K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
174
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
259